Albert M Kim

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 9

Top Venues

Diabetes, obesity & metabolism

Nature medicine

Health science reports

Science translational medicine

Pfizer Inc

David Geffen School of Medicine at UCLA (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Pfizer Inc

United States

Vice President, Clinical Research Head

Education History

David Geffen School of Medicine at UCLA

United States

PHD

Publications

Aditi R Saxena, Stephanie-An Lyle, Kaivan Khavandi, Ruolun Qiu, Mark Whitlock, William P Esler, Albert M Kim
A phase 2a, randomized, double-blind, placebo-controlled, three-arm, parallel-group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF-06835919 in patients with non-alcoholic fatty liver disease and type 2 diabetes. Diabetes, obesity & metabolism 25 (4) (2023)
Aditi R Saxena, Stephanie-An Lyle, Kaivan Khavandi, Ruolun Qiu, Mark Whitlock, William P Esler, Albert M Kim
A phase 2a, randomized, double-blind, placebo-controlled, three-arm, parallel-group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF-06835919 in patients with non-alcoholic fatty liver disease and type 2 diabetes. Diabetes, obesity & metabolism 25 (4) (2023)
Aditi R Saxena, Stephanie-An Lyle, Kaivan Khavandi, Ruolun Qiu, Mark Whitlock, William P Esler, Albert M Kim
A phase 2a, randomized, double-blind, placebo-controlled, three-arm, parallel-group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF-06835919 in patients with non-alcoholic fatty liver disease and type 2 diabetes. Diabetes, obesity & metabolism 25 (4) (2023)
Aditi R Saxena, Stephanie-An Lyle, Kaivan Khavandi, Ruolun Qiu, Mark Whitlock, William P Esler, Albert M Kim
A phase 2a, randomized, double-blind, placebo-controlled, three-arm, parallel-group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF-06835919 in patients with non-alcoholic fatty liver disease and type 2 diabetes. Diabetes, obesity & metabolism (2022)
Aditi R Saxena, Stephanie-An Lyle, Kaivan Khavandi, Ruolun Qiu, Mark Whitlock, William P Esler, Albert M Kim
A phase 2a, randomized, double-blind, placebo-controlled, three-arm, parallel-group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF-06835919 in patients with non-alcoholic fatty liver disease and type 2 diabetes. Diabetes, obesity & metabolism (2022)
Roberto A Calle, Neeta B Amin, Santos Carvajal-Gonzalez, Trenton T Ross, Arthur Bergman, Sudeepta Aggarwal, Collin Crowley, Anthony Rinaldi, Jessica Mancuso, Naresh Aggarwal, Veena Somayaji, Malgorzata Inglot, Theresa A Tuthill, Kou Kou, Magalie Boucher, Greg Tesz, Robert Dullea, Kendra K Bence, Albert M Kim, Jeffrey A Pfefferkorn, William P Esler
ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials. Nature medicine 27 (10) (2021)
Aditi R Saxena, Donal N Gorman, Ryan M Esquejo, Arthur Bergman, Kristin Chidsey, Clare Buckeridge, David A Griffith, Albert M Kim
Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial. Nature medicine 27 (6) (2021)
Neeta B Amin, Santos Carvajal-Gonzalez, Julie J Purkal, Tong Zhu, Collin Crowley, Sylvie Perez, Kristin Chidsey, Albert M Kim, Bryan Goodwin
Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis. Science translational medicine 11 (520) (2020)
Almasa Bass, Anna Plotka, Khurshid Mridha, Catherine Sattler, Albert M Kim, David R Plowchalk
Pharmacokinetics, pharmacodynamics, and safety of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, in healthy subjects when administered in co-mixture with recombinant human hyaluronidase: A phase 1 randomized trial. Health science reports 1 (9) (2018)

Albert M Kim.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Albert M Kim